Communique #44
24 May, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE New recommendations Baricitinib upgraded to a conditional recommendation The Disease-Modifying Treatment and Chemoprophylaxis Panel has reviewed the latest evidence for baricitinib and determined that in hospitalised adults with COVID-19 who require supplemental oxygen, baricitinib probably reduces the risk of death. As a result, the Taskforce has made the following conditional recommendation: Consider using...